HENGRUI PHARMA(01276)

59.250+0.750+1.28%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- AH Share Premium and Deviation Rankings for July 10
  Stock News · 07-10 16:24
  AH Share Premium and Deviation Rankings for July 10
- Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab Injection Application
  Stock News · 07-10 15:04
  Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab Injection Application
- Movement Alert｜Hengrui Pharma Rises 3.08% in Regular Trading, UBS Reiterates Buy Rating on Positive Weight-Loss Drug Data
  Market Focus · 07-10 10:01
  Movement Alert｜Hengrui Pharma Rises 3.08% in Regular Trading, UBS Reiterates Buy Rating on Positive Weight-Loss Drug Data
- UBS Reiterates 'Buy' on Hengrui Pharma, Citing Positive Weight-Loss Drug Data and Attractive Valuation
  Stock News · 07-09 17:20
  UBS Reiterates 'Buy' on Hengrui Pharma, Citing Positive Weight-Loss Drug Data and Attractive Valuation
- AH Share Premium and Deviation Data for July 8th
  Stock News · 07-08 16:23
  AH Share Premium and Deviation Data for July 8th
- Movement Alert｜Hengrui Medicine Rises 3.6% in Regular Trading, Proprietary Anti-Tumor Drug SHR-4685 Approved for Clinical Trials
  Market Focus · 07-08 09:53
  Movement Alert｜Hengrui Medicine Rises 3.6% in Regular Trading, Proprietary Anti-Tumor Drug SHR-4685 Approved for Clinical Trials
- Are "Old Economy" Stocks Signaling a Market Shift?
  Deep News · 07-06
  Are "Old Economy" Stocks Signaling a Market Shift?
- AH Share Premium and Deviation Data for July 6th
  Stock News · 07-06
  AH Share Premium and Deviation Data for July 6th
- Movement Alert｜Hengrui Pharma Rises 4.01% in Regular Trading, Pharmaceutical Sector Rallies Amid Multiple Drug Approval Catalysts
  Market Focus · 07-06
  Movement Alert｜Hengrui Pharma Rises 4.01% in Regular Trading, Pharmaceutical Sector Rallies Amid Multiple Drug Approval Catalysts
- AH Share Premium and Deviation Rankings for July 3rd
  Stock News · 07-03
  AH Share Premium and Deviation Rankings for July 3rd
- Movement Alert｜Hengrui Pharma Rises 3.2% in Regular Trading, Multiple New Drug Approvals and Priority Review Catalyze Gains
  Market Focus · 07-03
  Movement Alert｜Hengrui Pharma Rises 3.2% in Regular Trading, Multiple New Drug Approvals and Priority Review Catalyze Gains
- Hengrui Pharma Gets Nod to Trial Drug Combination for Hepatocellular Carcinoma
  MT Newswires Live · 07-03
  Hengrui Pharma Gets Nod to Trial Drug Combination for Hepatocellular Carcinoma
- Hengrui Pharma Reports Cumulative Share Buyback Totaling 13.47 Million A-Shares as of June 30
  Stock News · 07-02
  Hengrui Pharma Reports Cumulative Share Buyback Totaling 13.47 Million A-Shares as of June 30
- Hengrui Pharma Gains Regulatory Nod for Clinical Trials of Three Drug Candidates
  Stock News · 07-02
  Hengrui Pharma Gains Regulatory Nod for Clinical Trials of Three Drug Candidates
- HENGRUI PHARMA Keeps H-Share Capital Steady, Ups A-Share Treasury Stock via RMB 66.1 Million Buy-back in June
  Bulletin Express · 07-02
  HENGRUI PHARMA Keeps H-Share Capital Steady, Ups A-Share Treasury Stock via RMB 66.1 Million Buy-back in June
- Hengrui Pharma Shares Surge Over 6% on New Drug Indication Approval and International Expansion Success
  Stock News · 07-02
  Hengrui Pharma Shares Surge Over 6% on New Drug Indication Approval and International Expansion Success
- Movement Alert｜Hengrui Pharma Rises 3.72% in Regular Trading, Pharmaceutical Sector Rally and Multiple Drug Approvals Drive Gains
  Market Focus · 07-02
  Movement Alert｜Hengrui Pharma Rises 3.72% in Regular Trading, Pharmaceutical Sector Rally and Multiple Drug Approvals Drive Gains
- AH Share Premium and Deviation Rankings as of July 1st Close
  Stock News · 07-01
  AH Share Premium and Deviation Rankings as of July 1st Close
- AH Share Premium and Deviation Rankings as of June 30th Close
  Stock News · 06-30
  AH Share Premium and Deviation Rankings as of June 30th Close
- AH Share Premium and Deviation Data for June 29th
  Stock News · 06-29
  AH Share Premium and Deviation Data for June 29th
Company Profile
Company Name
HENGRUI PHARMA
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.hrs.com.cn
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.
- 03-26
  Annual Report
  2025 ANNUAL REPORT
  2025 ANNUAL REPORT

1D
5D
Day
Week
Month

Loading ...

High

61.750

Open

59.050

Volume%

1.12

Low

57.700

58.500

T/O Rate

1.75%

To The Moon

HENGRUI PHARMA(01276)

Company Profile

Most Discussed